drugset / Trial / NCT07326813

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

NCT07326813

Phase 3 Recruiting 477 enrolled InventisBio Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.

Timeline

Start
2026-01-12
Primary completion
2027-07-12
Completion
2027-12-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator CRAVACITINIB Small molecule
Subject D-2570 Unknown

Indications